VivoSeq
Oncology

Anaplastic Astrocytoma

35

Pipeline Programs↗

4

Active Trials↗

19

Companies Involved↗

Anaplastic Astrocytoma is a moderately active landscape with 35 programs across 19 companies. The most active players are Bristol-Myers Squibb, Pfizer, SymBio Pharmaceuticals. 8 therapies are approved with 8 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

54/100

Pipeline Velocity

0/100

Mech. Concentration

7/100

Completion Rate

63/100

Attrition Rate

24/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 1Pfizer logo

Pfizer

1 program

Phase 2S

SymBio Pharmaceuticals

1 program

Phase 2M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 2Regeneron logo

Regeneron

1 program

Phase 2Sanofi logo

Sanofi

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical1

Procarbazine Hydrochloride

Radiation Therapy Oncology Group

Phase 14

Cediranib Maleate

National Cancer Institute (NCI)

Telaglenastat Hydrochloride

National Cancer Institute (NCI)

TG02

European Organisation for Research and Treatment of Cancer - EORTC

CC-90010

Bristol-Myers Squibb

Phase 214

Antineoplaston A10

Burzynski Research Institute

Bendamustine Hydrochloride

SymBio Pharmaceuticals

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Bevacizumab

Bio-Thera Solutions

Etoposide

Avyxa

Phase 38

Eflornithine

USWM, LLC (dba US WorldMeds)

Temozolomide

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Lomustine

Azurity Pharmaceuticals

Carmustine

Melissa K Accordino

Semustine

Merck & Co.

Approved8

Carboplatin

Avyxa

Valacyclovir

Glaxo Dba Glaxosmithkline

Ixabepilone

R-Pharm

Romidepsin

Teva

Fingolimod

Novartis

Analysis

Modality Breakdown

91%

Small molecule

32 of 35 classified programs — the dominant modality here.

9%ALL OTHERSMonoclonal antibody13%Protein / enzyme13%RNA therapy13%

Small molecule leads; the ring shows all 35 classified programs, each share of the total. Modality classified for 95% of 37 pipeline programs.

Analysis

Trial Status

21

clinical trials

Completed10 · 48%
Terminated5 · 24%
Active, not recruiting3 · 14%
Recruiting1 · 5%
Unknown status1 · 5%
Suspended1 · 5%

Clinical Trials

Trial Activity

21 trials

DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
Recruiting·—·Phase 2·NCT06264388·33 enrolled
Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma
Active, not recruiting·National Cancer Institute (NCI)·Phase 1·NCT03528642·40 enrolled
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT03919071·58 enrolled
A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients With IDH Mutant, Low to Intermediate Grade Gliomas
Active, not recruiting·NRG Oncology·Phase 2·NCT03180502·120 enrolled
Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma
Completed·—·Phase 2·NCT00003470·27 enrolled
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma
Completed·National Cancer Institute (NCI)·Phase 1·NCT00458731·57 enrolled
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma
Completed·Alliance for Clinical Trials in Oncology·Phase 2·NCT00003621·29 enrolled
Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma.
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 1·NCT03224104·71 enrolled
A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma
Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00606008·30 enrolled
Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT00335075·151 enrolled
Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse
Completed·Pfizer logoPfizer·Phase 2·NCT00003775·60 enrolled
Antineoplaston Therapy in Treating Adult Patients With Anaplastic Astrocytoma
Completed·—·Phase 2·NCT00003537·19 enrolled
Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas
Completed·Radiation Therapy Oncology Group logoRadiation Therapy Oncology Group·Phase 3·NCT00004259·230 enrolled
SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745)
Completed·Merck & Co. logoMerck & Co.·Phase 2·NCT00783393·32 enrolled
Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma
Suspended·NNorthwell Health·Phase 1/2·NCT01386710·54 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)